Accumulation of C16 ceramide occurs during the development of insulin resistance and CerS6 silencing may be a potential target for the treatment of insulin resistance, obesity, and type 2 diabetes [37]. Here, CERS6 is linked to obesity due to melanocortin 4 receptor deficiency.